Camizestrant extends survival for advanced breast cancer patients

Switching to camizestrant significantly extended progression-free survival in patients with advanced breast cancer and ESR1 mutations, delaying disease progression. This new approach also maintained patients' quality of life. A recent study found that camizestrant, a next-generation oral SERD, improved progression-free survival by nearly seven months compared to continuing aromatase inhibitor therapy. The study focused on patients whose cancer developed ESR1 mutations. The research suggests that early intervention with camizestrant, guided by ctDNA testing, could become a new standard of care. While overall survival data is still pending, the treatment showed a favorable safety profile.